BCLI insider transaction filings
BRAINSTORM CELL THERAPEUTICS INC. — 45 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-28. Screen BCLI transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 2 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 2.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| FRENKEL JACOB A — Director | 1 | — | — | 1 |
| Pitts Peter Joe — Executive Chairman, Director | 1 | — | — | 1 |
Recent Form 4 filings — BRAINSTORM CELL THERAPEUTICS INC.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-28 | 4 | FRENKEL JACOB A — Director | Grant/award (A): 100,000 @ $0 | EDGAR |
| 2026-07-28 | 4 | Pitts Peter Joe — Executive Chairman, Director | Grant/award (A): 900,000 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | Lebovits Chaim — President & CEO | Grant/award (A): 1,800,000 @ $0 | EDGAR |
| 2026-05-29 | 4 | Yablonka Uri — EVP & Chief Business Officer, Director | Grant/award (A): 150,000 @ $0 | EDGAR |
| 2026-05-29 | 4 | Patlis Alla — See Remarks | Grant/award (A): 100,000 @ $0 | EDGAR |
| 2026-05-29 | 4 | FRENKEL JACOB A — Director | Grant/award (A): 200,000 @ $0 | EDGAR |
| 2026-05-29 | 4 | ARBEL IRIT — Director | Grant/award (A): 120,000 @ $0 | EDGAR |
| 2026-05-20 | 4 | Bairu Menghisteab — Director | Grant/award (A): 150,000 (derivative) @ $0.70 | EDGAR |
| 2026-05-20 | 4 | Polverino Anthony J. — Director | Grant/award (A): 150,000 (derivative) @ $0.70 | EDGAR |
| 2026-05-20 | 4 | HARTOUNIAN HARTOUN — Director | Grant/award (A): 225,000 (derivative) @ $0.70 | EDGAR |
| 2026-05-20 | 4 | Lindborg Stacy — Director | Grant/award (A): 150,000 (derivative) @ $0.70 | EDGAR |
| 2026-05-20 | 4 | Naor Nir — Director | Grant/award (A): 180,000 (derivative) @ $0.70 | EDGAR |
| 2026-05-20 | 4 | Dagher Ibrahim B. — Director | Grant/award (A): 225,000 (derivative) @ $0.70 | EDGAR |
| 2025-01-07 | 4 | Dagher Ibrahim B. — Chief Medical Officer | Grant/award (A): 50,000 @ $0 | EDGAR |
| 2025-01-03 | 4 | HARTOUNIAN HARTOUN — EVP, Chief Operating Officer | Grant/award (A): 50,000 @ $0 | EDGAR |
| 2025-01-03 | 4 | Lebovits Chaim — President & CEO | Grant/award (A): 120,000 @ $0 | EDGAR |
| 2025-01-03 | 4 | FRENKEL JACOB A — Director | Grant/award (A): 40,000 @ $0 | EDGAR |
| 2025-01-03 | 4 | Polverino Anthony J. — Director | Grant/award (A): 24,000 @ $0 | EDGAR |
| 2025-01-03 | 4 | Yablonka Uri — EVP & Chief Business Officer, Director | Grant/award (A): 40,000 @ $0 · Grant/award (A): 20,000 @ $0 | EDGAR |
| 2025-01-03 | 4 | Patlis Alla — See Remarks | Grant/award (A): 40,000 @ $0 | EDGAR |
| 2025-01-03 | 4 | Naor Nir — Director | Grant/award (A): 30,666 @ $0 | EDGAR |
| 2025-01-03 | 4 | Lindborg Stacy — Director | Grant/award (A): 20,000 @ $0 | EDGAR |
| 2025-01-03 | 4 | Bairu Menghisteab — Director | Grant/award (A): 24,000 @ $0 | EDGAR |
| 2025-01-03 | 4 | ARBEL IRIT — Director | Grant/award (A): 30,666 @ $0 | EDGAR |
| 2024-10-02 | 4 | Lebovits Chaim — President & CEO | Purchase (P): 22,000 @ $0.23 · Purchase (P): 1,836 @ $3.43 | EDGAR |
| 2024-07-31 | 4/A | Lebovits Chaim — President & CEO | Purchase (P): 15,000 @ $0.52 | EDGAR |
| 2024-07-31 | 4/A | Lebovits Chaim — President & CEO | Purchase (P): 25,000 @ $0.58 · Purchase (P): 25,000 @ $0.64 | EDGAR |
| 2024-07-31 | 4/A | Lebovits Chaim — President & CEO | Purchase (P): 20,000 @ $0.47 · Purchase (P): 10,000 @ $0.47 · Purchase (P): 10,000 @ $0.49 | EDGAR |
| 2024-07-31 | 4/A | Lebovits Chaim — President & CEO | Purchase (P): 66,300 @ $0.37 | EDGAR |
| 2024-07-31 | 4/A | Lebovits Chaim — President & CEO | Purchase (P): 135,000 @ $0.38 | EDGAR |
| 2024-07-31 | 4/A | Lebovits Chaim — President & CEO | Purchase (P): 15,000 @ $0.52 | EDGAR |
| 2024-07-31 | 4/A | Lebovits Chaim — President & CEO | Purchase (P): 130,000 @ $0.55 · Purchase (P): 115,072 @ $0.53 | EDGAR |
| 2024-07-24 | 4 | Dagher Ibrahim B. — Chief Medical Officer | Sale (S): 63,000 @ $0.35 | EDGAR |
| 2024-06-25 | 4 | HARTOUNIAN HARTOUN — EVP, Chief Operating Officer | Grant/award (A): 30,000 @ $0 · Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2024-06-03 | 4 | Lebovits Chaim — President & CEO | Grant/award (A): 15,000 @ $0.52 | EDGAR |
| 2024-05-23 | 4 | Lebovits Chaim — President & CEO | Grant/award (A): 25,000 @ $0.58 · Grant/award (A): 25,000 @ $0.64 | EDGAR |
| 2024-05-14 | 4 | Lebovits Chaim — President & CEO | Grant/award (A): 20,000 @ $0.47 · Grant/award (A): 10,000 @ $0.47 · Grant/award (A): 10,000 @ $0.49 | EDGAR |
| 2024-05-07 | 4 | Lebovits Chaim — President & CEO | Grant/award (A): 66,300 @ $0.37 | EDGAR |
| 2024-05-07 | 4 | Lebovits Chaim — President & CEO | Grant/award (A): 135,000 @ $0.38 | EDGAR |
| 2024-04-25 | 4 | Lebovits Chaim — President & CEO | Grant/award (A): 15,000 @ $0.52 | EDGAR |
| 2024-04-19 | 4 | Lebovits Chaim — President & CEO | Grant/award (A): 130,000 @ $0.55 · Grant/award (A): 115,072 @ $0.53 | EDGAR |
| 2024-03-13 | 4 | Lindborg Stacy — Co-Chief Executive Officer | Grant/award (A): 241,935 @ $0 | EDGAR |
| 2024-03-13 | 4 | Yablonka Uri — EVP & Chief Business Officer, Director | Grant/award (A): 109,426 @ $0 | EDGAR |
| 2024-03-13 | 4 | Patlis Alla — See Remarks | Grant/award (A): 65,246 @ $0 | EDGAR |
| 2024-03-13 | 4 | Lebovits Chaim — President & CEO | Grant/award (A): 305,198 @ $0 | EDGAR |
Recent 8-K events — BRAINSTORM CELL THERAPEUTICS INC.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-30 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-28 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-15 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-31 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-27 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-13 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-09 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-14 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.02 — Results of Operations and Financial Condition 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-06 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=BCLI returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →